Charts
Earnings and dividend calendar
Vaccine stocks news
In the most recent trading session, Astrazeneca (AZN) closed at $71.42, indicating a +0.38% shift from the previous trading day.
On Thursday, Merck & Co Inc MRK announced that its sales for the third quarter reached $16.66 billion, which is a 4% increase compared to the same period last year. This figure surpassed the expected amount of $16.47 billion.
Baby Boomer investors who are dissatisfied with the decreasing interest rates on their savings and CDs might find dividend stocks appealing at this time.
The upcoming years could be challenging for the big pharmaceutical company, but the future seems more promising.
ALL-REMOTE COMPANY/WILMINGTON, Del.--(BUSINESS WIRE)--Phreesia announced that it will release its fiscal third quarter 2025 financial results after the close of market trading on Monday, Dec. 9, 2024.
NEW YORK, NY / ACCESSWIRE / October 31, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Novavax, Inc. ("Novavax, Inc.") (NASDAQ:NVAX) concerning possible violations of federal securities laws. On October 16, 2024, NVAX announced the Food and Drug Administration placed a clinical hold on the development of the company's combination influenza and Covid-19 (CIC) shot and its stand-alone influenza vaccine.
NEW YORK, NY / ACCESSWIRE / October 31, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Novavax, Inc. ("Novavax" or the "Company") (NASDAQ:NVAX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
The Merck & Co., Inc. Q3 2024 Earnings Call is scheduled for October 31, 2024, at 09:00 AM ET. Key company participants include Peter Dannenbaum, Rob Davis, Caroline Litchfield, and Dean Li. Various conference call participants from different financial institutions will also be present.
Pfizer exceeded expectations for both revenue and adjusted earnings per share, thanks to the unexpected success of its COVID-related products. However, the mixed reaction after the earnings report indicates that Pfizer must focus on its growth opportunities outside of COVID. It seems that PFE has likely moved beyond its lowest points from early 2024, showing that the market believes the toughest times are behind it.
After Pfizer (PFE) reported better-than-expected earnings for the third quarter and increased its full-year forecast, CEO Albert Bourla appeared on Market Domination to talk about the "remarkable quarter." He highlighted that both Pfizer's earnings and revenue, as well as its COVID and non-COVID sectors, exceeded expectations.